Literature DB >> 25631097

NF1 single and multi-exons copy number variations in neurofibromatosis type 1.

Apolline Imbard1, Eric Pasmant2, Audrey Sabbagh3, Armelle Luscan2, Magali Soares4, Philippe Goussard4, Hélène Blanché5, Ingrid Laurendeau6, Salah Ferkal7, Michel Vidaud2, Stéphane Pinson8, Christine Bellanne-Chantelot9, Dominique Vidaud2, Pierre Wolkenstein10, Béatrice Parfait2.   

Abstract

Neurofibromatosis type 1 (NF1) is caused by dominant loss-of-function mutations of the tumor suppressor NF1 containing 57 constitutive coding exons. A huge number of different pathogenic NF1 alterations has been reported. The aim of the present study was to evaluate the usefulness of a multiplex ligation-dependent probe amplification (MLPA) approach in NF1 patients to detect single and multi-exon NF1 gene copy number variations. A genotype-phenotype correlation was then performed in NF1 patients carrying these types of genetic alterations. Among 565 NF1 index cases from the French NF1 cohort, single and multi-exon deletions/duplications screening identified NF1 partial deletions/duplications in 22 patients (~4%) using MLPA analysis. Eight single exon deletions, 11 multiple exons deletions, 1 complex rearrangement and 2 duplications were identified. All results were confirmed using a custom array-CGH. MLPA and custom array-CGH allowed the identification of rearrangements that were missed by cDNA/DNA sequencing or microsatellite analysis. We then performed a targeted next-generation sequencing of NF1 that allowed confirmation of all 22 rearrangements. No clear genotype-phenotype correlations were found for the most clinically significant disease features of NF1 in patients with single and multi-exons NF1 gene copy number changes.

Entities:  

Mesh:

Year:  2015        PMID: 25631097     DOI: 10.1038/jhg.2015.6

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  23 in total

1.  Automated comparative sequence analysis identifies mutations in 89% of NF1 patients and confirms a mutation cluster in exons 11-17 distinct from the GAP related domain.

Authors:  C Mattocks; D Baralle; P Tarpey; C ffrench-Constant; M Bobrow; J Whittaker
Journal:  J Med Genet       Date:  2004-04       Impact factor: 6.318

2.  Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference.

Authors: 
Journal:  Arch Neurol       Date:  1988-05

3.  A highly sensitive genetic protocol to detect NF1 mutations.

Authors:  María Carmen Valero; Yolanda Martín; Elisabete Hernández-Imaz; Alba Marina Hernández; Germán Meleán; Ana María Valero; Francisco Javier Rodríguez-Álvarez; Dolores Tellería; Concepción Hernández-Chico
Journal:  J Mol Diagn       Date:  2011-03       Impact factor: 5.568

4.  Elevated risk for MPNST in NF1 microdeletion patients.

Authors:  T De Raedt; H Brems; P Wolkenstein; D Vidaud; S Pilotti; F Perrone; V Mautner; S Frahm; R Sciot; E Legius
Journal:  Am J Hum Genet       Date:  2003-03-26       Impact factor: 11.025

5.  The genetic aspects of neurofibromatosis.

Authors:  J C Carey; B J Baty; J P Johnson; T Morrison; M Skolnick; J Kivlin
Journal:  Ann N Y Acad Sci       Date:  1986       Impact factor: 5.691

6.  An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes.

Authors:  D F Easton; M A Ponder; S M Huson; B A Ponder
Journal:  Am J Hum Genet       Date:  1993-08       Impact factor: 11.025

7.  Novel and recurrent mutations in the NF1 gene in Italian patients with neurofibromatosis type 1.

Authors:  Alessandro De Luca; Annalisa Schirinzi; Anna Buccino; Irene Bottillo; Lorenzo Sinibaldi; Isabella Torrente; Angela Ciavarella; Tania Dottorini; Roberto Porciello; Sandra Giustini; Stefano Calvieri; Bruno Dallapiccola
Journal:  Hum Mutat       Date:  2004-06       Impact factor: 4.878

8.  NF1 molecular characterization and neurofibromatosis type I genotype-phenotype correlation: the French experience.

Authors:  Audrey Sabbagh; Eric Pasmant; Apolline Imbard; Armelle Luscan; Magali Soares; Hélène Blanché; Ingrid Laurendeau; Salah Ferkal; Michel Vidaud; Stéphane Pinson; Christine Bellanné-Chantelot; Dominique Vidaud; Béatrice Parfait; Pierre Wolkenstein
Journal:  Hum Mutat       Date:  2013-08-26       Impact factor: 4.878

9.  Unravelling the genetic basis of variable clinical expression in neurofibromatosis 1.

Authors:  Audrey Sabbagh; Eric Pasmant; Ingrid Laurendeau; Béatrice Parfait; Sébastien Barbarot; Bernard Guillot; Patrick Combemale; Salah Ferkal; Michel Vidaud; Patrick Aubourg; Dominique Vidaud; Pierre Wolkenstein
Journal:  Hum Mol Genet       Date:  2009-05-05       Impact factor: 6.150

10.  Deletions of NF1 gene and exons detected by multiplex ligation-dependent probe amplification.

Authors:  A De Luca; I Bottillo; M C Dasdia; A Morella; V Lanari; L Bernardini; L Divona; S Giustini; L Sinibaldi; A Novelli; I Torrente; A Schirinzi; B Dallapiccola
Journal:  J Med Genet       Date:  2007-12       Impact factor: 6.318

View more
  9 in total

1.  Alternative outcomes of pathogenic complex somatic structural variations in the genomes of NF1 and NF2 patients.

Authors:  Meng-Chang Hsiao; Arkadiusz Piotrowski; Andrzej Brunon Poplawski; Tom Callens; Chuanhua Fu; Ludwine Messiaen
Journal:  Neurogenetics       Date:  2017-03-11       Impact factor: 2.660

2.  Decoding NF1 Intragenic Copy-Number Variations.

Authors:  Meng-Chang Hsiao; Arkadiusz Piotrowski; Tom Callens; Chuanhua Fu; Katharina Wimmer; Kathleen B M Claes; Ludwine Messiaen
Journal:  Am J Hum Genet       Date:  2015-07-16       Impact factor: 11.025

3.  Neurofibromatosis Type 1 Molecular Diagnosis: The RNA Point of View.

Authors:  Eric Pasmant; Dominique Vidaud
Journal:  EBioMedicine       Date:  2016-04-30       Impact factor: 8.143

4.  qEva-CRISPR: a method for quantitative evaluation of CRISPR/Cas-mediated genome editing in target and off-target sites.

Authors:  Magdalena Dabrowska; Karol Czubak; Wojciech Juzwa; Wlodzimierz J Krzyzosiak; Marta Olejniczak; Piotr Kozlowski
Journal:  Nucleic Acids Res       Date:  2018-09-28       Impact factor: 16.971

Review 5.  Challenges in the diagnosis of neurofibromatosis type 1 (NF1) in young children facilitated by means of revised diagnostic criteria including genetic testing for pathogenic NF1 gene variants.

Authors:  Hildegard Kehrer-Sawatzki; David N Cooper
Journal:  Hum Genet       Date:  2021-12-20       Impact factor: 4.132

6.  Genotype-Phenotype Correlations in Neurofibromatosis Type 1: Identification of Novel and Recurrent NF1 Gene Variants and Correlations with Neurocognitive Phenotype.

Authors:  Filomena Napolitano; Milena Dell'Aquila; Chiara Terracciano; Giuseppina Franzese; Maria Teresa Gentile; Giulio Piluso; Claudia Santoro; Davide Colavito; Anna Patanè; Paolo De Blasiis; Simone Sampaolo; Simona Paladino; Mariarosa Anna Beatrice Melone
Journal:  Genes (Basel)       Date:  2022-06-23       Impact factor: 4.141

7.  Editorial: Copy Number Variants in Neurological Disorder.

Authors:  Giulia Gentile; Sebastiano Cavallaro
Journal:  Curr Genomics       Date:  2018-09       Impact factor: 2.236

8.  Genetic diagnosis of neurofibromatosis type 1: targeted next- generation sequencing with Multiple Ligation-Dependent Probe Amplification analysis.

Authors:  Yah-Huei Wu-Chou; Tzu-Chao Hung; Yin-Ting Lin; Hsing-Wen Cheng; Ju-Li Lin; Chih-Hung Lin; Chung-Chih Yu; Kuo-Ting Chen; Tu-Hsueh Yeh; Yu-Ray Chen
Journal:  J Biomed Sci       Date:  2018-10-05       Impact factor: 8.410

9.  Mutational spectrum of NF1 gene in 24 unrelated Egyptian families with neurofibromatosis type 1.

Authors:  Nahla N Abdel-Aziz; Ghada Y El-Kamah; Rabab A Khairat; Hanan R Mohamed; Yehia Z Gad; Akmal M El-Ghor; Khalda S Amr
Journal:  Mol Genet Genomic Med       Date:  2021-06-03       Impact factor: 2.183

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.